BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND IGH AND Clinical Outcome
45 results:

  • 1. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
    Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinicopathologic features of adult EBV-associated B-cell lymphoproliferative disease.
    Wörner S; Mueller-Hermelink HK; Voelker HU
    Pathol Res Pract; 2018 Feb; 214(2):207-212. PubMed ID: 29258765
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder.
    Lorenzi L; Lonardi S; Essatari MH; Pellegrini V; Fisogni S; Gazzola A; Agostinelli C; Vermi W; Rossi G; Massarelli G; Pileri SA; Facchetti F
    Virchows Arch; 2016 Apr; 468(4):441-50. PubMed ID: 26762526
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma.
    Aricò A; Ferraresso S; Bresolin S; Marconato L; Comazzi S; Te Kronnie G; Aresu L
    PLoS One; 2014; 9(11):e111817. PubMed ID: 25372838
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis.
    Abdul-Wahab A; Tang SY; Robson A; Morris S; Agar N; Wain EM; Child F; Scarisbrick J; Neat M; Whittaker S
    J Am Acad Dermatol; 2014 Jun; 70(6):1010-20. PubMed ID: 24679486
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Conventional and molecular cytogenetic characterization of Burkitt lymphoma with bone marrow involvement in Brazilian children and adolescents.
    De Souza MT; Hassan R; Liehr T; Marques-Salles TJ; Boulhosa AM; Abdelhay E; Ribeiro RC; Silva ML
    Pediatr Blood Cancer; 2014 Aug; 61(8):1422-6. PubMed ID: 24668946
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.
    Hockley SL; Else M; Morilla A; Wotherspoon A; Dearden C; Catovsky D; Gonzalez D; Matutes E
    Br J Haematol; 2012 Aug; 158(3):347-54. PubMed ID: 22594855
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
    Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
    J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
    Tomita N; Tokunaka M; Nakamura N; Takeuchi K; Koike J; Motomura S; Miyamoto K; Kikuchi A; Hyo R; Yakushijin Y; Masaki Y; Fujii S; Hayashi T; Ishigatsubo Y; Miura I
    Haematologica; 2009 Jul; 94(7):935-43. PubMed ID: 19535347
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Early-stage gastric MALT lymphoma: is it a truly localized disease?
    Siakantaris MP; Pangalis GA; Dimitriadou E; Kontopidou FN; Vassilakopoulos TP; Kalpadakis C; Sachanas S; Yiakoumis X; Korkolopoulou P; Kyrtsonis MC; Bobotsis P; Androulaki A; Patsouris E; Panayiotidis P; Angelopoulou MK
    Oncologist; 2009 Feb; 14(2):148-54. PubMed ID: 19204322
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Molecular characteristics and prognostic significance of Bcl-2/igh gene rearrangement in Serbian follicular lymphoma patients.
    Radojkovic M; Ristic S; Colovic M; Cemerikic-Martinovic V; Radojkovic D; Krtolica K
    Neoplasma; 2008; 55(5):421-7. PubMed ID: 18665753
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.
    Cikota BM; Tukić LJ; Tarabar OT; Magić ZM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):535-42. PubMed ID: 18365550
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
    Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
    Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Primary follicular lymphoma of the testis and epididymis in adults.
    Bacon CM; Ye H; Diss TC; McNamara C; Kueck B; Hasserjian RP; Rohatiner AZ; Ferry J; Du MQ; Dogan A
    Am J Surg Pathol; 2007 Jul; 31(7):1050-8. PubMed ID: 17592272
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome.
    Lai R; Lefresne SV; Franko B; Hui D; Mirza I; Mansoor A; Amin HM; Ma Y
    Mod Pathol; 2006 Nov; 19(11):1498-505. PubMed ID: 16980950
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/igh positive cells: Is the end of molecular monitoring near?
    Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
    Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.